[1]林 星,董田甜.罕见病药品保障模式的国际经验与启示 ——以酶替代疗法药品为例[J].卫生经济研究,2024,41(11):54-57.
 LIN Xing,DONG Tiantian.International Experience and Enlightenment of Drug Security Model for Rare Diseases ——Taking Enzyme Replacement Therapy Drugs as an Example[J].Journal Press of Health Economics Research,2024,41(11):54-57.
点击复制

罕见病药品保障模式的国际经验与启示
——以酶替代疗法药品为例
分享到:

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
41
期数:
2024年11期
页码:
54-57
栏目:
他山之石
出版日期:
2024-10-31

文章信息/Info

Title:
International Experience and Enlightenment of Drug Security Model for Rare Diseases
——Taking Enzyme Replacement Therapy Drugs as an Example
作者:
林 星1董田甜1
1.中国药科大学国际医药商学院,江苏 南京 211198
Author(s):
LIN Xing DONG Tiantian
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
罕见病酶替代疗法药品政策国际经验
Keywords:
rare disease enzyme replacement therapy drug policy international experience
分类号:
R95
文献标志码:
A
摘要:
目的:以酶替代疗法药品为例,分析我国罕见病药品保障现状,在借鉴国外经验的基础上,提出完善我国罕见病药品保障政策的建议。方法:通过政策梳理及文献分析,了解我国酶替代疗法药品保障现状,总结澳大利亚、俄罗斯、新西兰对酶替代疗法药品的基本保障模式。结果:澳大利亚、俄罗斯、新西兰的典型保障模式对罕见病患者酶替代疗法用药均有不同程度的补助,具有国家财政参与、药品衔接保障和多部门协同的共同特点。结论:我国可借鉴国际经验,通过设立国家专项基金、建立疾病与药品间政策衔接机制、加强信息网络建设等举措,完善罕见病药品保障体系。
Abstract:
Objective Taking enzyme replacement therapy drugs as an example, to analyze the current situation of drug security for rare disease in China, and to propose suggestions for improving drug security policy for rare disease in China based on international experience. Methods Policy review and literature analysis was used to understand the current situation of drug security for enzyme replacement therapy in China, and the basic security models for enzyme replacement therapy drugs in Australia, Russia, and New Zealand were summarized. Results The typical security models of Australia, Russia, and New Zealand provided varying degrees of subsidies for enzyme replacement therapy drugs for patients with rare disease, with common characteristics of national financial participation, drug connection guarantee, and multi departmental collaboration. Conclusion China can learn from international experience and improve drug security system for rare diseases by establishing a national special fund, building a policy connection mechanism between diseases and drugs, and strengthening information network construction.

参考文献/References:

[1] 黄如方,邵文斌.共同富裕下的中国罕见病药物支付[R].北京:寇德罕见病中心,2022.
[2] 关轶茹,相维,张方.澳大利亚救生药物计划及对我国罕见病医疗救助制度的启示[J].中国卫生政策研究,2015,8(08):51-55.
[3] Australian Government Department of Health and Age Care.About the Life Saving Drug Program[EB/OL].(2023-04-01)[2023-12-23].https://www.health.gov.au/our-work/life-saving-drugs-program/about-the-lsdp.
[4] Президент России.Указ одсоздании фонда 《Круг добра》 для поддержки детей с тяжёлыми жизнеугрожающими и хрони- ческими заболеваниями, в том числе редкими (орфанными)[EB/OL].(2021-01-06)[2023-12-28].http://www.kremlin.ru/acts/n ews/64863.
[5] Президент России.Расширен список детских заболеваний, финансовое обеспечение которых осуществляется за фсчёт фонда 《Круг добра》[EB/OL].(2023-02-06)[2023-12-28].http://www.kremlin.ru/acts/news/70463.
[6] Phamaceutical Management Agency.Evaluation of PHARMAC’scommercial approach to fundmedicines for rare disorders[EB/OL].(2017-06-07)[2024-01-03].https://pharmac.govt.nz/assets/2017-06-final-Grant-Thornton-evaluation.pdf.
[7] Phamaceutical Management Agency.2019 Report Funding Medi-cines for Rare Disorders[EB/OL].(2019-02-22)[2024-01-03].https:// pharmac.govt.nz/assets/2019-Report-Funding-Medicines-for-Rare-Disorders-PDF-version.pdf.
[8] Phamaceutical Management Agency.Funding for rare disorders[EB/OL].(2023-11-13)[2024-01-03].https://pharmac.govt.nz/me-dicine-funding-and-supply/the-funding-process/from-application-to-funded-medicine-how-we-fund-a-medicine/medicin-es-for-rare-disorders.

相似文献/References:

[1]胡善联.国内外罕见病的保障政策研究[J].卫生经济研究,2018,(05):3.
[2]陈馨仪,符 晓,王安石,等.罕见病患者治疗及保障研究[J].卫生经济研究,2020,(09):40.
 CHEN Xin-yi,FU Xiao,WANG An-shi,et al.Research on the Treatment and Guarantee of Patients with Rare Diseases[J].Journal Press of Health Economics Research,2020,(11):40.
[3]王子琪,闵连星,田兴军,等.我国罕见病医保政策的现状及优化路径[J].卫生经济研究,2021,38(11):22.
 WANG Zi-qi,MIN Lian-xing,TIAN Xing-jun,et al.The Situation and Optimization Path of Medical Insurance Policy for Rare Diseases in China[J].Journal Press of Health Economics Research,2021,38(11):22.
[4]李奕昊,唐贵忠.罕见病用药可负担性评价及医保政策研究[J].卫生经济研究,2022,39(4):53.
 LI Yi-hao,TANG Gui-zhong.Affordability Evaluation of Drugs for Rare Diseases and Research on Medical Insurance Policy[J].Journal Press of Health Economics Research,2022,39(11):53.
[5]张永理,张开然.我国罕见病患者医疗保障现状及改进建议[J].卫生经济研究,2023,40(1):53.
 ZHANG Yongli,ZHANG Kairan.Medical Security Status and Improvement Suggestions for Patients with Rare Diseases in China[J].Journal Press of Health Economics Research,2023,40(11):53.
[6]朱 坤sup>.中国罕见病保障机制:现状、挑战与建议[J].卫生经济研究,2024,41(01):23.
 ZHU Kun.Security Mechanism for Rare Diseases in China: Progress,Problems and Suggestions[J].Journal Press of Health Economics Research,2024,41(11):23.
[7]谭清立,丘丽莹.城市普惠型商业医疗保险比较研究[J].卫生经济研究,2024,41(02):23.
 TAN Qingli,QIU Liying.Comparative Study on Urban Inclusive Commercial Medical Insurance[J].Journal Press of Health Economics Research,2024,41(11):23.
[8]王珺琦,殷 悦,唐文熙.医保准入视角下罕见病用药经济价值评估的 难点、方法与建议[J].卫生经济研究,2024,41(09):58.
 WANG Junqi,YIN Yue,TANG Wenxi.Difficulties, Methods, and Suggestions for Assessing the Economic Value of Rare Disease Medications from the Perspective of Health Insurance Access[J].Journal Press of Health Economics Research,2024,41(11):58.
[9]沈杨阳.中国罕见病问题及综合保障机制研究[J].卫生经济研究,2024,41(12):1.
 SHEN Yangyang.Study on the Problems of Rare Diseases and Comprehensive Protection Mechanisms in China[J].Journal Press of Health Economics Research,2024,41(11):1.
[10]刘慧玲,赵恒伯,谢志勤,等.2022年江西省罕见病治疗费用核算分析 ——基于SHA2011[J].卫生经济研究,2025,42(02):46.
 LIU Huiling,ZHAO Hengbo,XIE Zhiqin,et al.Analysis of Rare Disease Treatment Cost Accounting in Jiangxi Province in 2022 ——Based on SHA2011[J].Journal Press of Health Economics Research,2025,42(11):46.

更新日期/Last Update: 2024-10-31